Rising global focus on innovative oral vaccines underscores a transformative shift in immunization strategies, emphasizing ease of administration and enhanced patient compliance. Key advancements, including thermostable formulations and needle-free delivery systems, drive sustained growth in accessibility, global vaccination rates, and disease prevention outcomes.
New Delhi, Jan. 13, 2025 (GLOBE NEWSWIRE) — The global oral vaccines market was valued USD 3,985.9 million in 2024 and is anticipated to reach USD 8,800 million by 2033 at a CAGR of 9.2% during the forecast period 2025-2033.
The rising prevalence of infectious diseases such as cholera, typhoid, and rotavirus continue to propel the market. According to WHO, 535,321 cholera cases and 4,007 deaths were reported globally in 2023, underscoring the critical need for effective vaccination solutions. Typhoid fever, affecting 9 million people annually with 110,000 deaths, further highlights the demand for preventive measures. Regulatory milestones, such as the FDA’s 2016 approval of Vaxchora—the first oral cholera vaccine in the U.S.—demonstrate the commitment of government and healthcare organizations to addressing these public health challenges.
Download Free Sample Pages @ https://www.astuteanalytica.com/request-sample/oral-vaccines-market
Collaborations between global health organizations and governments have also accelerated vaccine distribution. The WHO prequalification of vaccines like Rotavac and Rotasiil has facilitated their inclusion in national immunization programs in low- and middle-income countries. Partnerships with initiatives like Gavi, the Vaccine Alliance, have enabled widespread adoption of oral vaccines, particularly in regions lacking healthcare infrastructure.
Government initiatives are pivotal in propelling the oral vaccine market by expediting the development, approval, and distribution of innovative solutions. Regulatory agencies worldwide are prioritizing the advancement of oral vaccines to meet critical needs in infectious disease prevention and pandemic readiness. Notably, the U.S. Food and Drug Administration (FDA) has streamlined approval pathways for vaccines targeting urgent public health concerns. For example, Vaxart, a biotechnology firm, received fast-track designation from the FDA for its oral COVID-19 vaccine candidate, underscoring the proactive role of regulatory bodies in fostering innovation within the oral vaccine sector.
Oral vaccines are increasingly recognized for their non-invasive delivery, ease of administration, and suitability for mass immunization campaigns in underserved areas. Innovations in vaccine formulations for improved stability and efficacy are further expanding their applications, addressing diseases in regions affected by natural disasters, conflict, or displacement.
However, the market faces challenges, including the need for oral vaccines to overcome the harsh gastrointestinal environment, which can compromise their potency. Researchers are addressing these barriers by developing novel mucosal adjuvants to enhance stability and efficacy, ensuring continued advancements in the field.
Key Findings in Oral Vaccines Market
| Market Forecast (2033) | US$ 8,800 Million |
| CAGR | 9.2% |
| Top Drivers |
|
| Top Trends |
|
| Top Challenges |
|
Technological Milestones: Innovation Spearheading Growth in the Global Oral Vaccines Market
The oral vaccines market is undergoing transformative advancements, driven by the need for safer, more accessible, and patient-friendly immunization solutions. As of December 2021, there were six different vaccine platforms, including an inactivated virus vaccine, DNA and mRNA vaccines, an adenovirus vector vaccine, a subunit vaccine, a virus-like vaccine and a lentivirus vaccine. Moreover, >194 candidate vaccines have been approved for clinical trials worldwide, showcasing significant progress in vaccine efficacy under challenging conditions. Thermostable oral vaccines are gaining traction enabling broader immunization coverage in underserved areas. Additionally, regulatory milestones like the WHO prequalification of oral cholera and rotavirus vaccines have paved the way for their inclusion in national immunization programs worldwide.
Key market players are actively investing in R&D, with many new oral vaccine candidates targeting diseases such as typhoid, tuberculosis, and polio expected to reach advanced clinical stages by 2025. Meanwhile, partnerships with global health organizations like Gavi, the Vaccine Alliance, are facilitating mass distribution campaigns, particularly in regions with high disease burden. These innovations, coupled with robust funding and policy support, are reshaping the market landscape, ensuring that oral vaccines remain a cornerstone of global preventive healthcare.
Evolving Demand: Targeted Immunization Strategies Transforming Global Vaccine Adoption
The demand for oral vaccines extends beyond traditional immunization, opening new avenues for targeted disease prevention and outbreak management. Since 2014, Gavi has been supporting the Global Oral Cholera Vaccine (OCV) Stockpile to aid emergency response, address humanitarian crises, and facilitate preventive vaccination in cholera-endemic countries. By the end of 2020, the stockpile had been utilized 87 times across 22 countries, with nearly 70 million doses distributed. Similarly, oral rotavirus vaccines have become a key tool in reducing infant mortality, particularly in countries with high rates of diarrhea-related deaths.
Innovations in oral vaccine technology are expanding their applicability, with at least five new vaccine candidates targeting emerging diseases such as norovirus and enterotoxigenic E. coli. Additionally, research into next-generation mucosal adjuvants is addressing challenges in vaccine stability, promising higher efficacy in harsh gastrointestinal environments. These developments align with a growing emphasis on personalized immunization programs, where oral vaccines are being explored for age-specific and population-tailored applications.
Customize this report to your needs: https://www.astuteanalytica.com/ask-for-customization/oral-vaccines-market
Future Outlook: Unlocking Growth Opportunities in the Oral Vaccines Landscape
The global oral vaccines market is poised for exponential growth, offering significant opportunities for manufacturers, healthcare providers, and investors. Collaborative efforts between governments, academic institutions, and private companies are driving the development of advanced oral vaccine platforms, with at least 20 ongoing clinical trials exploring novel delivery mechanisms.
Macro trends such as the rising prevalence of infectious diseases, increased investment in healthcare infrastructure, and the growing adoption of needle-free immunization solutions are set to propel market expansion. By 2033, oral vaccines are expected to account for a significant share of global immunization programs, driven by their affordability, ease of administration, and adaptability to low-resource settings. To capitalize on these opportunities, stakeholders must prioritize innovation, regulatory compliance, and accessibility, ensuring that oral vaccines continue to transform preventive healthcare and meet the evolving demands of global populations.
Oral Vaccines Market Key Players:
- Sanofi
- GSK
- Takeda Pharmaceuticals
- Soligenix
- Liquidia Technologies
- Elasmogen
- Abivax
- Oravax Medical
- Rapid Dose Therapeutics
- AVRO Life Science
- Prokarium Ltd
- Matinas Biopharma
- ACM Biolabs
- Alcami
- Other Prominent Players
Key Segments Covered in The Report
By Vaccine Type
- Live Attenuated
- Inactive
- Recombinant
- Subunit
- Others
By Application
- Polio
- Tuberculosis
- Rabies
- Influenza
- Cholera
- Cancer
- COVID 19
- Others
By Target Population
- Paediatric Population (Children)
- Adults
- Geriatric Population
By End Users
- Hospitals
- Clinics
- Vaccination Centres
- Home Care Settings
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- South America
Have questions? Inquire about this report before purchasing: https://www.astuteanalytica.com/inquire-before-purchase/oral-vaccines-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: [email protected]
Website: https://www.astuteanalytica.com/
LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: [email protected] Website: https://www.astuteanalytica.com/
The post Oral Vaccines Market Valuation is Set to Reach US$ 8,800 Million by 2033 | Astute Analytica first appeared on CXP – Customer Experience Asia.
